Atypical teratoid rhabdoid tumors (ATRT) are highly malignant brain tumors of early childhood that have been regarded as a homogenous entity characterized by inactivation of the SMARCB1/INI1 or SMARCA4/BRG1 genes as the only characteristic alteration. Recent studies suggest that similar to other embryonal tumors ATRT can also be divided into subgroups based on their mRNA or methylation profiles. Using microarray-based expression analysis of 12 patient ATRT specimens we demonstrated the existence of 2 subgroups of ATRT. One subgroup is characterized by high expression of OTX2, encoding a transcription factor involved in brain development. OTX2 expression was verified by immunohistochemistry and might function as a novel therapeutic target for this fatal tumor. High expression of OTX2 as well as expression of Kir7.1/ KCNJ13, TRPM3 and ENPP2, which have all previously been linked to either choroid plexus epithelium or choroid plexus tumors (CPTs), suggests a close histogenetic relation of this subgroup to CPTs.
INTRODUCTION
Atypical teratoid rhabdoid tumors (ATRTs) are highly malignant brain tumors that occur mainly during infancy and early childhood (1) . Genetically these tumors are characterized by bi-allelic inactivation or deletion of the SMARCB1/ INI1 gene or in rare cases of the SMARCA4/BRG1 gene (2) (3) (4) . The genome of ATRTs otherwise appear to be stable (5) . Recent studies suggest that ATRT can be divided into molecular subgroups based on RNA or methylation profiling (6, 7) . OTX2 (Orthodenticle homeobox 2) is a regulating transcription factor that has a crucial role in the development of the CNS. It is involved in the development of the cerebellum, pituitary, retina and the choroid plexus and in the regulation of neuronal precursors in the midbrain (8) (9) (10) . Furthermore, OTX2 is highly expressed in non-SHH subgroups of medulloblastoma, choroid plexus tumors (CPTs), and in retinoblastomas (11) (12) (13) . Adamson et al identified its role as a proto-oncogene in medulloblastomas. OTX2 also appears to be important for growth maintenance and proliferation in medulloblastomas (14, 15) . Recent studies suggest OTX2 might represent a therapeutic target (12, 16) .
MATERIALS AND METHODS

Tumor Tissue Samples
Twenty-five ATRT tissue specimens and 11 CPT (5 choroid plexus papilloma [CPP], 3 atypical choroid plexus papillomas [aCPP] , and 3 choroid plexus carcinoma [CPC] ) were retrieved from the archives of the Institute of Neuropathology, University of Bonn Medical Center (Bonn, Germany), and of the DGNN German Brain Tumor Reference Center (Bonn, Germany). All tumors were classified according to the WHO classification of CNS tumors (1, 17) . Immunohistochemistry (IHC) was performed on a semi-automated IHC Stainer (Tecan, Crailsheim, Germany) or a Ventana Benchmark XT Immunostainer (Roche Ventana, Darmstadt, Germany) with antibodies against SMARCB1/INI1 (BD Biosciences, Franklin Lakes, NJ), SMARCA4/BRG1 (Bethyl Laboratories, Montgomery, TX), OTX2 (Thermo Fisher Scientific, Rockford, IL), cytokeratins (LU-5; Bachem, Weil am Rhein, Germany), epithelial membrane antigen (EMA), vimentin, synaptophysin, smooth muscle actin (SMA), glial fibrillary acidic protein ([GFAP] Dako, Glostrup, Denmark). To identify SMARCB1/INI1 alterations we used the SALSA MLPA (multiplex ligation-dependent probe amplification) P258 (SMARCB1) kit (MRC-Holland), according to the manufacturer's protocol. After normalization of the assay against normal cerebellar tissue (FFPE material), a difference of minus threefold standard deviation from the mean was considered as heterozygous loss, a difference of minus fivefold standard deviation a homozygous loss. SMARCB1/INI1 mutations were identified by direct sequencing. Therefore polymerase chain reaction (PCR) products were purified using a PCR purification kit (Qiagen GmbH, Düsseldorf, Germany). Direct sequencing reactions were performed in duplicate (forward and reverse) by a commercial sequencing laboratory (Eurofins MWG Operon, Ebersberg, Germany) using 30 ng of PCR products.
DNA and RNA Extraction
Hematoxylin and eosin (H&E)-stained sections of each case were reviewed carefully prior to DNA/RNA extraction. All samples selected contained at least 80% of viable tumor. RNA and DNA extraction from 23 fresh tumor tissue specimens was performed as previously described in (18) . DNA from 19 formalin-fixed paraffin-embedded (FFPE) tumor tissues was extracted using the QIAamp DNA Mini Tissue Kit (Qiagen GmbH), according to the manufacturer's instructions.
Gene Expression Analysis
Approximately 200 ng of total RNA obtained from 12 ATRT and the 11 CPT were amplified and labeled prepared for microarray experiments using the Affymetrix WT Plus Reagent kit (Affymetrix, Santa Clara, CA), following the manufacturer's instructions. RNA quality parameters in quality control analysis were appropriate. For expression analysis, HTA_2.0 arrays (Affymetrix) were used and scanned with the GC Scanner 3000 (G7 update; Affymetrix). For hierarchical clustering, the following parameters were used: clustering method, unweighted pair group mean average; similarity measure, correlation; ordering function, average value. The threshold for SD of normalized signals was higher than 0.15. A total of 6,648 probe sets remained. For group comparison 1-way analysis of variance (1-way ANOVA) was used. ANOVA p value (Condition pair) < 0.05 was considered significant. Gene set enrichment analysis was performed as described elsewhere (19, 20) .
Molecular Inversion Probe Assay
Molecular inversion probe array was performed using the custom-designed OncoScan FFPE Express330K platform version 2 (Affymetrix) to identify copy number gains and losses; 13 ATRT samples were included. Molecular inversion probe assay was performed as previously described in (13, 21) .
RESULTS
Cohort
For this study 25 patients were included. Median age at diagnosis was <9 months (range, 1-117 months) (Table) . Male to female ratio was almost balanced (male: female, 1.18:1). Tumor location was found equally distributed in supra-and infratentorial areas. Contact of the tumor to the ventricular system was described in 6 patients. Twenty-four specimens showed an immunohistochemical loss of the (Table) .
Gene Expression Analysis
We performed gene expression analysis in a representative series of 12 ATRT. Despite the small number of cases, unsupervised hierarchical cluster analysis based on gene expression revealed 2 groups with distinct expression patterns, referred to as Group 1 (n ¼ 7) and Group 2 (n ¼ 5) (Fig. 1) . On closer examination, Group 1 could be divided in 2 further subgroups suggesting a closer relation between these groups. ANOVA was performed to identify the most differentially expressed genes between the 2 main groups (Supplementary Data Table S1 ). In Group 2, OTX2 was 33.6-fold higher expressed than in Group 1 (ANOVA p value: < 0.001). OTX2 expression levels of ATRT Group 2 were equal to the levels of the CPT (Fig. 2) . In addition, tyrosinase (TYR) and microphthalmia-associated transcription factor (MITF) were expressed at higher levels in Group 2 (24.1-and 11.7-fold, respectively; ANOVA p value: < 0.001) (Fig. 2) . Our microarray data also showed that Kir7.1/KCNJ13 expression was significantly higher in all 5 ATRT of Group 2 (fold change 12.63; ANOVA p value: < 0.001; Supplementary Data Table  S1 ), although expression was not as high as in the CPT cohort. ENPP2 and TRPM3, which are also reported in CPT, were found to be highly expressed in Group 2 (fold change 50.03 and 43.09, respectively; ANOVA p value: < 0.001; Supplementary Data Table S1 ). In a gene set enrichment analysis, the melanogenesis pathway was enriched in Group 2, though it was not significant ( Fig. 4 ; p value: 0.776).
Immunohistochemistry
To verify these results we stained paraffin sections of 21 representative ATRT with a highly specific monoclonal antibody against OTX2 protein. Nuclear staining with antibodies against OTX2 in >5% of tumor cells was observed in 8 of 21 stained specimens (Table; Fig. 3 ). Microarray data were available for 9 of 21 ATRT. All 4 ATRT that showed high expression of OTX2 in the microarray-based analysis also showed strong nuclear staining with antibodies against OTX2 whereas in the others no significant staining was observed.
Further immunohistochemical analyses (e.g. cytokeratin, EMA, GFAP, Map2c, synaptophysin, SMA, vimentin) did not show significant differences in the expression profiles between Group 1 and Group 2.
Chromosomal Alterations of Chromosome 22 and SMARCB1
Thirteen ATRT samples were included in the molecular inversion probe assay (Group 1, 8 samples; Group 2, 5 samples). Almost all Group 2 tumors showed whole losses of Chromosome 22 (4 of 5 samples), whereas only 3 of 8 showed monosomy of Chromosome 22 in the other group; however, this was not significant. Alterations affecting SMARCB1/INI1 were present in all tumor samples included except the tumor sample with loss of SMARCA4/BRG1 expression. The extent of alterations ranged from focal to total homozygous loss of SMARCB1/INI1, heterozygous loss and mutations (point mutations or small deletions). Significant differences in the kind of alteration could not be observed between the subgroups (Table; Fig. 1 ).
Clinical Correlation
Patients in Group 2 were young (mean 5.5 months; range 1-17 months), whereas in the other group also older patients were included (mean 16 months; range 4-117 months). There was a slight male predominance in Group 1 and a tendency towards female gender in Group 2 (p ¼ 0.044; Fisher exact test). No significant difference could be observed between supra-or infratentorial localization (p ¼ 0.413; Fisher exact test). For 5 of 9 patients of Group 2 contact to the ventricle was known, while only in 1 case contact to the ventricular system was mentioned in Group1 (1 of 14; p ¼ 0.05; Fisher exact test). 
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DISCUSSION
To date, ATRT have been regarded as a homogeneous group of tumors that is defined by a stable genome and biallelic inactivation of the SMARCB1/INI1 gene, or in rare cases, of the SMARCA4/BRG1 gene (2-5). In recent years, distinct molecular subgroups in other pediatric brain tumors have been identified and validated. For example, medulloblastomas can be divided into at least 4 molecular subgroups (based on expression pattern and epigenetic profiles) characterized by disparate transcriptional signatures, mutational spectra, copy number profiles and, most importantly, clinical features (22) . The exact number of meaningful subgroups depends on the methods used and number of cases. For example, Cho et al identified 6 subgroups in medulloblastoma (23) .
Recent studies on the RNA as well as on the methylation profiles suggest that ATRT may also consist of distinct molecular subgroups (6, 7) . The exact nature as well as the number of these subgroups has not yet been fully determined. Torchia et al reported that expression of ASCL1, a regulator of notch, was correlated with a superior 5-year survival (6) . In another study Johann et al (7) found 3 distinct subgroups based on expression and methylation profiles.
Our study supports the hypothesis that ATRT are not a homogeneous tumor entity but consist of at least 2 subgroups with distinct expression profiles. One group was characterized by expression of the OTX2 as well as TYR genes. This is consistent with findings of Johann et al who found a subgroup of ATRT characterized by expression of TYR, MITF, and OTX2. In retinal pigment epithelium, OTX2 acts as an activator for TYR directly or indirectly via MITF (24) , but the role of OTX2 in the context of ATRT has not been investigated to date. However, it can be hypothesized that OTX2 acts as a transcriptional activator for TYR in this context as well.
A reason for inter-tumoral heterogeneity within an entity can be that an oncogenic event hits specific cells of origin at different stages of differentiation (25) . In this context, OTX2 might be interpreted as a lineage marker. OTX2 has been found to have a crucial role in the development of the choroid plexus (8) and it is highly expressed in CPT (13) (Fig. 2) . These results might indicate a close relationship between ATRT and CPT, a relationship that has previously been suggested by others (26, 27) . We could also demonstrate high expression of Kir7.1/KCNJ13, ENPP2, and TRPM3 in ATRT Group 2. TRPM3 has been described previously in context of CPT (13, 28) . ENPP2 is highly expressed in choroid plexus epithelium (29) and CPT (Fig. 2) , and focal chromosomal gains were found in CPT (13) . Kir7.1/KCNJ13 is known as a marker for CPT and Schittenhelm et al demonstrated that Kir7.1/ KCNJ13 was expressed in a few ATRT samples; they also discuss diagnostic problems to differentiate between ATRT and CPT as well (27, 30) . These results also suggest a close relationship between CPT and ATRT Group 2. Whether choroid plexus (epithelium) progenitor cells are the origin of ATRT Group 2 may be considered.
On the other hand, OTX2 is a transcription factor that has been identified as an oncogene in the context of medulloblastomas (14) . Therefore, OTX2 might also function as an oncogene in ATRT and its expression may be important for tumor maintenance in ATRT Group 2 tumors, as previous described for medulloblastoma (15) . This would mean that OTX2 might also represent a potential future therapeutic target (12, 16) .
Johann et al (7) found parallels to melanoma biology mainly based on overexpression of MITF and enrichment of the melanogenesis pathway. We confirmed both results in our gene set enrichment analysis and the ANOVA test. Melanogenesis pathway enrichment in ATRT Group 2, however, was not significant in our gene set enrichment analysis. That might be due to the small number of tumor samples included. ATRT subgroups showed distinct alterations of chromosome 22 or the SMARCB1/INI1 gene, respectively.
Our analyses revealed more large copy number losses of chromosome 22 in the ATRT Group 2, but this was not significant. We could not identify a different distribution of cases with focal alterations of the SMARCB1/INI1 gene or mutation frequency in the subgroups. However, the transcriptional profile of the tumors may depend on the total absence of SMARCB1/INI1 or the presence of a mutated protein in the SWI/SNF complex.
In summary our data show that ATRT can be divided into molecular subgroups and that OTX2 represented a reliable immunohistochemical marker for one of these subgroups; however, the biological role of OTX2 in ATRT still has to be determined. 
